atrys Chief Executive Officer and Managing Director, Dr. James Campbell said: “The GMP manufacturing run for PAT-DX1 started during the quarter and subsequent to the end of the quarter has recently been successfully completed.
The Company expects the additional product characterisation and specification testing will be completed by Q2 CY2024.
We were also pleased to announce that after the end of the quarter positive preclinical data concerning deoxymabs in animal models of the autoimmune disease vasculitis was presented during the plenary session at a leading international workshop. This potentially opens up a new therapeutic area for Patrys to develop or partner its deoxymab technology
Ann: Appendix 4C - Quarterly - 31 March 2024, page-2
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
